Matches in Wikidata for { <http://www.wikidata.org/entity/Q91672036> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q91672036 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q91672036 description "scientific article published on 04 July 2019" @default.
- Q91672036 description "wetenschappelijk artikel" @default.
- Q91672036 description "наукова стаття, опублікована 4 липня 2019" @default.
- Q91672036 description "գիտական հոդված հրատարակված 2019 թվականի հուլիսի 4-ին" @default.
- Q91672036 name "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobic" @default.
- Q91672036 name "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobic" @default.
- Q91672036 type Item @default.
- Q91672036 label "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobic" @default.
- Q91672036 label "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobic" @default.
- Q91672036 prefLabel "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobic" @default.
- Q91672036 prefLabel "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobic" @default.
- Q91672036 P1433 Q91672036-38BE2255-B7B1-449A-8C3F-5A05C5241B62 @default.
- Q91672036 P1476 Q91672036-C993B782-9ACE-4643-97D3-2F29D3630FB4 @default.
- Q91672036 P2093 Q91672036-04667B21-F7BF-4998-AC66-69E272C42FDC @default.
- Q91672036 P2093 Q91672036-1BBE82B6-BCA8-420E-9807-05B40633C7B9 @default.
- Q91672036 P2093 Q91672036-1F60189D-0A7F-4041-9BF7-A0CFCB52013E @default.
- Q91672036 P2093 Q91672036-2A1741FA-C4BE-47B2-99A3-B28565A9E679 @default.
- Q91672036 P2093 Q91672036-52EC320E-12D5-44FA-9E59-A534B637A610 @default.
- Q91672036 P2093 Q91672036-5B19B73B-C3D9-4AD5-975A-C0A74B75037B @default.
- Q91672036 P2093 Q91672036-7B449723-8E54-46E3-9141-F692BB981750 @default.
- Q91672036 P2093 Q91672036-A94325CF-630D-49A1-B014-3CEB18BAD185 @default.
- Q91672036 P2093 Q91672036-AE8045B0-31A3-4048-9314-29804A947438 @default.
- Q91672036 P2093 Q91672036-BBE02B03-7A2F-42F7-B737-657B5DF0B65B @default.
- Q91672036 P2093 Q91672036-BFF25694-4307-421A-BF8A-CC7040C8DFDB @default.
- Q91672036 P2093 Q91672036-F9061B78-1174-459B-B9EC-EF27E6AE3215 @default.
- Q91672036 P304 Q91672036-FA6DBCC7-1A8C-41F8-A0CC-DBAFA3C84C40 @default.
- Q91672036 P31 Q91672036-0FA18406-D32F-458D-8940-35B2B03C564F @default.
- Q91672036 P356 Q91672036-77A1CA0B-E8FF-4322-9489-414505EFCCAE @default.
- Q91672036 P478 Q91672036-8B80B513-61E9-4643-9543-983BB191CF3C @default.
- Q91672036 P50 Q91672036-37750000-CA7B-48B1-A5AE-4ED968614F95 @default.
- Q91672036 P50 Q91672036-C5FAD99C-0C07-495F-BF29-A2E456343A26 @default.
- Q91672036 P577 Q91672036-EE88D02C-FEF2-434E-9FAA-821C796E8C13 @default.
- Q91672036 P698 Q91672036-C12709C2-D92E-4F1B-AE40-5AEFF9CFDB3B @default.
- Q91672036 P921 Q91672036-1206B260-8789-4ADF-9F0A-E351DDAC664B @default.
- Q91672036 P921 Q91672036-18614042-AB46-4110-B20F-6A8BCBA2EA60 @default.
- Q91672036 P921 Q91672036-438C9791-5139-4D29-8F20-F65764B58C94 @default.
- Q91672036 P356 J.ANTIVIRAL.2019.104543 @default.
- Q91672036 P698 31279073 @default.
- Q91672036 P1433 Q4775352 @default.
- Q91672036 P1476 "Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1" @default.
- Q91672036 P2093 "Chloe Orkin" @default.
- Q91672036 P2093 "Douglas Cunningham" @default.
- Q91672036 P2093 "EMERALD study group" @default.
- Q91672036 P2093 "Erika Van Landuyt" @default.
- Q91672036 P2093 "Erkki Lathouwers" @default.
- Q91672036 P2093 "Federico Pulido" @default.
- Q91672036 P2093 "Frank A Post" @default.
- Q91672036 P2093 "John Jezorwski" @default.
- Q91672036 P2093 "Kimberley Brown" @default.
- Q91672036 P2093 "Magda Opsomer" @default.
- Q91672036 P2093 "Romana Petrovic" @default.
- Q91672036 P2093 "Veerle Hufkens" @default.
- Q91672036 P304 "104543" @default.
- Q91672036 P31 Q13442814 @default.
- Q91672036 P356 "10.1016/J.ANTIVIRAL.2019.104543" @default.
- Q91672036 P478 "170" @default.
- Q91672036 P50 Q47006685 @default.
- Q91672036 P50 Q87874621 @default.
- Q91672036 P577 "2019-07-04T00:00:00Z" @default.
- Q91672036 P698 "31279073" @default.
- Q91672036 P921 Q155954 @default.
- Q91672036 P921 Q422604 @default.
- Q91672036 P921 Q42824827 @default.